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Original articleHigh plasma levels of endothelin-1 enhance the predictive
value of preclinical atherosclerosis for future cerebrovascular
and cardiovascular events: a 20-year prospective study
Giuseppina Novo, Angela Sansone, Manfredi Rizzo, Francesco P. Guarneri,
Claudio Pernice and Salvatore NovoBackground and purpose Clinical and experimental
evidence suggests that endothelin-1 (Et-1) plays a role in
cardiac and vascular disease. In the present study, we
investigated the prognostic significance of Et-1 for
cerebrovascular and cardiovascular outcome, in a 20-year
follow-up.
Methods We studied 82 originally healthy individuals,
referred to our Unit of Cardiovascular Prevention, to
evaluate the presence of asymptomatic carotid lesions. We
subdivided these individuals into two groups, according to
the plasma values of Et-1 (respectively <— or >2.7 pg/ml).
Traditional cardiovascular risk factors were investigated,
and by carotid ultrasound examination, we distinguished
between normal individuals and those with intima–media
thickening or asymptomatic carotid plaque.
ResultsMajor cardiac and cerebral events (all-cause death,
myocardial infarction, revascularization procedures, fatal
and nonfatal stroke) were registered in 41 individuals and
significantly more in those with high vs. low Et-1 levels
(95 vs. 5%; P<0.0001). Furthermore, by logistic multivariate
regression analysis, we found that among all evaluated
baseline clinical and laboratory variables, hypertension
[odds ratio (OR): 20.4 (3.3–127), PU0.001], high Et-1
concentrations [OR: 1.4 (1.0–1.8), PU0.02] and the
presence of intima–media thickness or asymptomaticopyright © Italian Federation of Cardiology. Una
1558-2027  2014 Italian Federation of Cardiologycarotid plaque [OR: 3.7 (1.14–12.1), PU0.02] were
independent predictors of future events. Finally,
integrating technical and laboratory data, high levels
of Et-1 have defined a high risk of major cardiac and
cerebral event and stroke at follow-up, which increased in
relation to the progression of carotid atherosclerosis
(P<0.05).
Conclusion Et-1 plasmatic levels significantly influence the
cardiovascular and cerebrovascular risk profile, beyond
traditional cardiovascular risk factors and preclinical carotid
atherosclerosis.
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The endothelial function is strictly dependent on anatom-
ical continuity of themonolayer cell aswell as its functional
integrity. In the presence of cardiovascular risk factors, the
protective role of endothelium seems to deteriorate, con-
figuring the so-called ‘endothelial dysfunction’,1 charac-
terized by an impaired vasomotor response to main
endothelium-dependent vasodilating stimuli, as well as
a proinflammatory and anticoagulant action. Endothelial
dysfunction represents the earliest event in the develop-
ment of atherosclerotic plaque; it actually occurs when a
structural lesion is still not evident. Therefore, its evalu-
ation could be useful for an early stratification of patients at
risk of cardiovascular events.2
Endothelin-1 (Et-1) is a peptide secreted primarily by
vascular endothelial cells, with potent vasoconstrictor3
and mitogenic properties, and it is involved in the hydro-
saline homeostasis through its interactions with therenin–angiotensin–aldosterone system (RAAS), stimu-
lating the sympathetic nervous system too. A large num-
ber of studies have reported the pleiotropic action of this
peptide on cardiac and renal function, as well as on
vascular cell growth. Et-1 has been related to the pro-
gression of atherosclerotic disease, and a pathogenic role
has been suggested for heart failure4; in addition, other
studies have suggested the short-term prognostic signifi-
cance of Et-1 in patients with acute myocardial infarc-
tion5 (AMI) after primary angioplasty as well as in those
with ischemic stroke.6 These findings highlight the role
of Et-1 as an important mediator of cardiovascular and
cerebrovascular diseases and further provide important
therapeutic insights into the prevention of atherosclero-
sis, vascular remodeling, left ventricular hypertrophy and
hypertensive nephropathy.
In the present study, we aimed to assess whether baseline
Et-1 levels may be predictors of future cardiovascular anduthorized reproduction of this article is prohibited.
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individuals, screened for the presence of asymptomatic
carotid lesions in our Centre for Early Diagnosis of
Preclinical andMultifocal Atherosclerosis and for Cardio-
vascular Prevention. The follow-up period was 20 years.
We, therefore, aimed to test the hypothesis that measur-
ing levels of this peptide can provide information not only
on the progression of atherosclerosis disease, but can also
be considered to be predictive of the risk of developing
ischemic stroke and/or cardiovascular events, helping
to define the prognosis, independently of common risk
factors.
Methods
Study designs and participants
We performed a 20-year prospective study in all the
patients through periodic outpatient visits for detecting
the occurrence of cerebrovascular and cardiovascular
events eventually. The considered endpoints were
two: the first composite endpoint included the following
major adverse cardiovascular and cerebrovascular events
(MACCEs): cardiovascular death, AMI, new revasculari-
zation procedures (coronary angioplasty, coronary artery
bypass graft) and cerebrovascular events (transient
ischemic attack and major or minor stroke); the second
endpoint included the occurrence of major stroke only.
AMI was defined by a prolonged episode of chest pain
with electrocardiogram and/or specific myocardial
enzyme changes, involving hospitalization and presumed
new ischemic electrocardiographic changes or new left
bundle branch block, occurred before cardiac biomarkers
were obtained or before cardiac biomarker values were
increased7; as to the second outcome, major stroke was
defined by the modified Rankin Scale8; finally sudden
cardiac death was defined by cardiac death with or with-
out symptoms suggestive of myocardial ischemia. The
causes of death were retrieved directly from the families
and were confirmed in all the cases by the general
practitioners on the basis of their own records (which
may include hospital records).
Our cohort included 82 adults, men and women, from 30
to 75 years (mean age of the whole population was
58.6 years; 56 15.97 in the first group with lower levels
of Et-1 and 61 14.18 in the second group with higher
levels of Et-1 – difference not significant). They were
baseline healthy individuals, all referred between 1990
and 1992 to our Centre for Early Diagnosis of Preclinical
and Multifocal Atherosclerosis and for Cardiovascular
Prevention for evaluating the presence of asymptomatic
carotid lesions through an ultrasound scan. Patients were
excluded if they had a history of peripheral artery disease,
coronary revascularization, angina pectoris, myocardial
infarction, carotid surgery or cerebrovascular event.
Patients underwent physical examination, biochemical
analysis and ultrasonography of the carotid arteries inpyright © Italian Federation of Cardiology. Unauorder to verify the clinical wellness and the presence of
atherosclerotic carotid lesions and to evaluate the impact
of main cardiovascular risk factors. The adopted pro-
cedures were in agreement with the Helsinki Declaration
of 1975 as revised in 1983 and were approved by the
Department Ethic Council. All patients gave their
informed consent for participating in the study, and at
admission answered a questionnaire on personal and
medical items, including age, medical history and use
of medications. Among the main cardiovascular risk fac-
tors, the presence of family history of cardiovascular
diseases (in a first-degree relative before 55 years),
hypertension (SBP or DBP respectively 140 or
90mmHg or pharmacological therapy with antihyper-
tensive drugs), diabetes (fasting glucose plasma concen-
trations higher than 126mg/dl or pharmacological therapy
with antidiabetic drugs or insulin), dyslipidemia (total
cholesterol >200mg/dl or pharmacological therapy with
statins) and smoking habits were considered. Sitting
blood pressure was measured twice on the right arm with
a random-zero sphygmomanometer. The average of two
measurements obtained on one occasion, separated by a
count of the pulse rate, was used in the present analysis.
Height and weight were recorded and BMI was
expressed as kg/m2. Participants were categorized as
having obesity if BMI was 30 kg/m2 or higher.
Biochemistry
A blood sample was drawn in the morning, before the
medical examination, after 12–14 h overnight fast. Total
cholesterol was quantified by standard enzymatic-colori-
metric methods.9 Et-1 was measured by a sensitive
enzyme immunoassay for human endothelin.10 The assay
is based on a sandwich method that uses two differing
capture and detection antiendothelin antibodies. A
monoclonal antiendothelin antibody, which did not react
with an endothelin C-terminal heptapeptide, was used as
an immobilized antibody. The Fab fragment of rabbit
antibodies against the endothelin C-terminal heptapep-
tide was used as an enzyme-labeled detector antibody
after being coupled with horseradish peroxidase 10.8 As
there is still no general agreement on which values can be
considered elevated for Et-1, we referred to the work of
Morganti et al.11 that considered increased Et-1 plasma
levels higher than 2.7 pg/ml for a population living at
sea level.
Ultrasound examination of the carotid arteries
B-mode real-time ultrasound was used to evaluate the
arterial wall thickness in the carotid arteries using a
Toshiba 270 SS machine with a built-in software and with
a 7.5–10.0MHz probe. The power output, focus, depth of
measurement and gain were standardized by using the
preset program incorporated within the software package
of the ultrasound equipment. The intima–media thick-
ness (IMT) was defined as the distance between the
echogenic line representing the intima–blood interfacethorized reproduction of this article is prohibited.
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Table 1 Baseline clinical characteristics, laboratory data and
ultrasonographic findings in relation to plasma values of
endothelin-1
Et-1 2.7 pg/ml
(n¼22)
Et-1 >2.7 pg/ml
(n¼60) P value
Female [n (%)] 11 (50%) 38 (63%) NS
Age (years) 5615.97 6114.18 0.15
Hypertension [n (%)] 13 (59%) 49 (81.6%) 0.03
Diabetes [n (%)] 10 (45.4%) 34 (56.6%) NS
Dyslipidemia [n (%)] 6 (27.3%) 22 (36.6%) NS
Smoking [n (%)] 3 (13.6%) 6 (10%) NS
Obesity [n (%)] 6 (27.3%) 12 (20%) NS
IMT/ACP [n (%)] 9 (41%) 48 (80%) 0.001
Et-1 (pg/ml) 1.490.68 6.092.79 <0.0001
Et-1, endothelin-1; IMT/ACP, intima–media thickening or asymptomatic carotid
plaque.and the outer echogenic line representing the adventitia
junction. After freezing the image, the measurement was
made with electronic callipers.
Patients were examined in the supine position, and each
carotid wall and segment were examined to identify the
thickest intimal–medial site. Three segments were
identified and measured in anterior and posterior planes
on each side: the distal 1 cm of the common carotid
proximal to the bifurcation, the bifurcation itself and
the proximal 1 cm of the internal carotid artery. At each
of these sites, we have determined the IMT, automati-
cally measured, and detected any possible plaque. We
primarily used the maximum carotid IMT value, which
was determined as the mean of the maximum IMT of
near-wall and far-wall measurements of both the left and
right side arteries for each of the three arterial segments.
If data on one of the walls or one of the sides were
missing, the maximum thickness of the available wall and
side was used. Ultrasound examination was performed by
one investigator (C.P.) blinded to the study and with no
possibility of reproducing the IMTmeasurement, to limit
the risk of a large interobserver variability.12
According to the guidelines of the joint European Society
of Hypertension/European Society of Cardiology, we
distinguished between ‘normal individuals’, if IMT
was less than 0.9mm, individuals with IMT if IMT
was more than 0.9, but less than 1.5mm and individuals
with asymptomatic carotid plaque (ACP), if IMT was
more than 1.5mm.13
Statistical analysis
The statistical analysis was performed using the software
Staview Program (SAS Institute Inc., Cary, North Car-
olina, USA). Differences in the investigated parameters
among study groups were assessed by the unpaired
Student’s t-test (for numeric variables) and by the x2
test (for nominal variables). Data were expressed as
mean standard deviation or as percentages. Multivari-
ate analysis (logistic regression) was used to assess the
potential independent effects of baseline variables on the
incidence of future events. A P value less than 0.05 was
considered statistically significant.
Results
Baseline clinical characteristics, laboratory data and ultra-
sonography findings in relation to plasma values of Et-1
are summarized in Table 1. Individuals with elevated
Et-1 levels11 (n¼ 60) had higher prevalence of most of
the traditional cardiovascular risk factors, including hy-
pertension (P¼ 0.03), carotid IMT or ACP (P¼ 0.001) in
relation to individuals with low Et-1 concentrations.
There were no significant differences in age and in the
presence of smoking, obesity and the other risk factors.
Table 2 shows the baseline clinical characteristics, labora-
tory data and ultrasonography findings in relation to theopyright © Italian Federation of Cardiology. Unaoccurrence of clinical events (n¼ 41), as registered in the
20-year follow-up in the group with elevated Et-1 levels.
At univariate analysis, individuals with high Et-1 levels
were mainly women (P< 0.004), were of older age
(P< 0.0001), had a higher prevalence of hypertension
(P< 0.0001) and carotid atherosclerosis (P< 0.001), and
had higher levels of Et-1 (P< 0.0001). Furthermore, by
logistic multivariate regression analysis, we found that
among all evaluated baseline clinical and laboratory vari-
ables, only hypertension [odds ratio (OR): 20.4, (3.3–127)
P¼ 0.001], high Et-1 concentrations [OR: 1.4, (1.0–1.8)
P¼ 0.02] and the presence of IMT or ACP [OR: 3.7,
(1.14–12.1) P¼ 0.02] were independent predictors of
future events.
According to the results on multivariate analysis, relating
high Et-1 plasma values and the presence of IMT/ACP
(intima–media thickening or ACP), we therefore wanted
to test whether the occurrence of MACCE (n¼ 41) at
follow-up was better defined integrating instrumental
data and plasma values of Et-1.
We found not only a higher prevalence of events among
individuals with higher values of Et-1 (95 vs. 5%,
P< 0.001) or in the presence of carotid plaque (90 vs.
12%, P< 0.001), but also that in the group with higher
Et-1 levels, the number of events increased in those
with carotid plaque at baseline, whereas in patients with
lower Et-1 levels, this relationship was not confirmed
(Fig. 1).
Therefore, higher values of Et-1 define a higher risk of
events at follow-up in patients with carotid atherosclero-
sis, whereas lower values of Et-1 do not significantly
influence the distribution of events at follow-up in
patients with carotid atherosclerosis (P< 0.05).
Similar data were found as it concerns the occurrence of
stroke (n¼ 24) at follow-up time. In fact, we found a
higher prevalence of events among individuals with
higher values of Et-1 (87.5 vs. 12.5%, P< 0.000). In
the group of patients with higher values of Et-1, the
distribution of events was significantly rising according to
the progression of carotid disease severity (P< 0.05),uthorized reproduction of this article is prohibited.
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Table 2 Logistic regression analysis of the baseline clinical characteristics, laboratory data and ultrasonographic findings in relation to the
occurrence of major cardiac and cerebral events in the group with higher levels of endothelin-1, as registered in the 20-year follow-up
Patients with MACCE
(n¼41) P value
Patients without events
(n¼41)
Logistic regression analysis
or (95% CI); P value
Female [n (%)] 14 (34) 0.004 35 (85) 1.248 (1.08–1.74); 0.012
Age (years) 6911 <0.0001 5112 1.00 (0.97–1.04); 0.69
Hypertension [n (%)] 39 (95) <0.0001 23 (56) 20.431 (3.28–127); 0.001
Diabetes [n (%)] 17 (42) 0.04 27 (66) 0.734 (0.23–2.28); 0.59
Dyslipidemia [n (%)] 8 (20) 0.01 20 (49) 0.418 (0.11–1.50); 0.18
Smoking [n (%)] 3 (7) NS 6 (15) 0.858 (0.14–5.70); 0.86
Obesity [n (%)] 6 (15) NS 12 (29) 0.894 (0.23–3.34); 0.86
IMT/ACP [n (%)] 37 (90) <0.0001 20 (49) 3.730 (1.14–12.12); 0.028
Et-1 >2.7 pg/ml [n (%)] 39 (95) <0.0001 21 (51) 1.372 (1.03–1.82); 0.029
CI, confidence interval; Et-1, endothelin-1; IMT/ACP, intima–media thickening or asymptomatic carotid plaque; MACCE, major cardiac and cerebral event.whereas in the group with lower Et-1 levels, it was not
(Fig. 2).
Discussion
According to our results, Et-1 plasmatic levels signifi-
cantly influence the cardiovascular and cerebrovascular
risk profile, beyond traditional cardiovascular risk factors
and preclinical carotid atherosclerosis.
Soon after the discovery of Et-1, this vasoactive substance
was reported to have several biological actions on cardiac
tissue. In human myocardium, in-vitro Et-1 has been
shown to exert a positive inotropic12–15 effect via sensit-
ization of cardiac myofilaments to calcium and activation
of the sodium proton exchanger. The positive inotropic
effect is accompanied by prolongation of the duration of
the action potential.16,17 This pharmacological action of
Et-1 may contribute to the proarrhythmogenic property
of the peptide. Et-1 also affects heart function indirectly
via profound coronary vasoconstriction and it is involvedpyright © Italian Federation of Cardiology. Unau
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endothelin-1.in the mechanism by which angiotensin induces cardiac
hypertrophy.
As regards the relation between plasma levels of Et-1 and
myocardial infarction, the role of Et-1 is both beneficial
and detrimental. Et-1 seems to play an important role in
causation of myocardial infarction,18 postinfarct scar for-
mation,19 left ventricular remodeling20 and in the prog-
nosis of myocardial infarction. In a study21 performed in
patients with ST-segment elevation myocardial infarc-
tion treated with primary percutaneous coronary inter-
vention, plasma levels of Et-1 measured after myocardial
infarction were found to be a strong predictor of 1-year
survival, independently of clinical and biochemical vari-
ables previously associated with a poor prognosis. The
above-mentioned studies, therefore, provided interesting
insights into the potential benefits of a therapy with Et-1
blockers, and showed not only a pathophysiological role
of this peptide, but also a prognostic significance, particu-
larly related to cardiovascular mortality.22thorized reproduction of this article is prohibited.
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siological role of this peptide in hemorrhagic as well as
ischemic stroke has already been reported.23 Stroke
causes an interruption in the normal blood flow of
cerebral vessels in a specific area. Et-1 receptors localized
in neurons, glial cells, and microvessel endothelial cells
accounted for a large volume of endothelin in the cerebral
circulation; under inflammatory conditions caused by
cytokines, the production of Et-1 from smooth muscle
cells is increased. Endothelin has a sustained vasocon-
strictive effect on cerebral vessels, which opposes the
homeostatic mechanism of the body that attempts to
dilate the vessels and move to the devoid area oxygen
and nutrients.9–23
Levels of Et-1 have been discovered actually to drasti-
cally increase in the cerebral spinal fluid of stroke patients
18 h after a stroke24 and have been shown to influence the
neurological outcome. Although strokes stem from a
variety of factors, hypertension and inflammation are
the most prominent contributors to stroke pathophysiol-
ogy. So the intense vasoconstrictive effect of Et-1 that
feeds the mechanisms of hypertension increases even
more the already detrimental vascular consequences
associated with hypertension and atherosclerosis.25
Therefore, the development of pharmacological strat-
egies for modifying the production and activity of this
potent vasoconstrictor peptide may be beneficial in
improving the outcome of brain and heart ischemia.26,27
The role of carotid IMT or ACP is consistent to previous
studies.28–30
In the present study, we performed a 20-year follow-up in
a group of 82 baseline healthy individuals, to evaluate the
occurrence of future cerebrovascular and cardiovascular
events in relation to the levels of Et-1.
So the limitations of our study are related to the small
sample of patients examined.
In conclusion, our study confirmed the presence of a
strong association between known cardiovascular risk
factors such as hypertension, carotid preclinical athero-
sclerosis27–30 and subsequent cardiovascular or cerebro-
vascular events. Nevertheless, the present study
suggested a possible role of Et-1, as a marker of endo-
thelial dysfunction, influencing primarily cerebrovascular
outcome. Moreover, it seems that elevated levels of Et-1
strongly enhance the role of preclinical carotid athero-
sclerosis as a predictor of MACCE.28–30
Therefore, recent studies31–36 have shown the import-
ance of different laboratory markers in risk stratification
of patients with coronary artery disease.
Similarly, several recent studies have demonstrated the
predictive validity of new markers. In particular, soluble
suppression of tumorigenicity 2 has a role as an early
marker of cardiovascular diseases, above all in heart
failure and ischemic heart diseases.37 Moreover, theopyright © Italian Federation of Cardiology. Unaserum osteoprotegerin is important in predicting coronary
artery disease.38 Recent study evaluated also the dosage
of salivary N-terminal probrain natriuretic peptide as a
predictive method for heart failure.39
The results of our study suggest the possibility of using a
new laboratory parameter, which is endothelin, to better
define the cerebrovascular and cardiovascular risk.
Given the demonstrated relationship to events at the
follow-up, a possible therapeutic intervention on Et-1
(e.g. with receptor antagonists for the Et-1 as bosentan
and ambrisentan, usually used for pulmonary hyperten-
sion) may not only have a positive effect on cardiac
function, but also an important role in preventing new
cardiovascular events, through a more accurate stratifica-
tion of patients, as well as avoiding permanent effects that
can result from a cerebral vascular accident.
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